克拉霉素
阿莫西林
幽门螺杆菌
微生物学
医学
抗生素
内科学
生物
作者
Takahisa Furuta,Mihoko Yamade,Takuma Kagami,Takahiro Suzuki,Tomohiro Higuchi,Shinya Tani,Yasushi Hamaya,Moriya Iwaizumi,Hiroaki Miyajima,Kazuo Umemura,Satoshi Osawa,Ken Sugimoto
出处
期刊:Gut
[BMJ]
日期:2020-02-12
卷期号:69 (11): 2056.2-2056
被引量:8
标识
DOI:10.1136/gutjnl-2020-320705
摘要
We read the manuscript written by Suzuki et al 1 with interest. They reported that the eradication rate of Helicobacter pylori attained by the dual therapy with vonoprazan and amoxicillin (VA-Dual) was almost the same as that attained by the triple therapy with vonoprazan, amoxicillin and clarithromycin (VAC-Triple), as previously reported by us.2 The most interesting point in this paper was that the VA-Dual therapy was superior to the VAC-Triple therapy in eradicating the clarithromycin-resistant strains of H. pylori . In this regard, the authors consider the possibilities of a type I error, the difference in the proportion of amoxicillin-resistant strains, and the excessive inhibition of gastric acid secretion …
科研通智能强力驱动
Strongly Powered by AbleSci AI